Our findings are in line with a previous study by Xu et al. who identified Vim+ circulating cells in metastatic prostate cancer patients using the Parsortix and confirmed their malignancy by genomic alterations (Xu et al. 2017). Here, VIM is linked to metastatic prostate carcinoma.